Cell Therapeutics, Inc. (CTIC: Quote) Tuesday announced the initiation of the commercial launch of Pixuvri in the European Union.
While the drug will enter Sweden, Denmark and Finland in September, it will be launched in Austria and Norway in early October and Germany, United Kingdom and the Netherlands in November. CTI plans to expand availability to France, Italy and Spain as well as other European countries in 2013.
Pixuvri was granted conditional marketing authorization by the European Commission in May and is the first medicinal product licensed in the E.U. to treat adult patients with multiply relapsed or refractory aggressive B-cell non-Hodgkin Lymphoma or NHL. In the E.U., there are around 37,000 new cases of aggressive B-cell NHL every year.
Click here to receive FREE breaking news email alerts for Cell Therapeutics Inc. and others in your portfolio
by RTT Staff Writer
For comments and feedback: firstname.lastname@example.org